Table S3. Baseline characteristics of the study patients at CKD Stages 3a, 3b or 4 for all predictors, stratified by outcome at 2- and 5-years

|  | 2-years | | 5-years | |
| --- | --- | --- | --- | --- |
| **Characteristic** | **No kidney failure**, N = 7,4051 | **Kidney failure**, N = 1141 | **No kidney failure**, N = 7,2801 | **Kidney failure**, N = 2391 |
| **Sex** |  |  |  |  |
| Female | 4,062 (54.9%) | 45 (39.5%) | 4,015 (55.2%) | 92 (38.5%) |
| Male | 3,343 (45.1%) | 69 (60.5%) | 3,265 (44.8%) | 147 (61.5%) |
| **Age (years)** |  |  |  |  |
| Mean (SD) | 74.1 (10.2) | 66.6 (11.7) | 74.2 (10.1) | 66.5 (12.5) |
| Median (IQR) | 75.0 (68.0, 81.0) | 67.0 (59.2, 74.0) | 75.0 (68.0, 82.0) | 67.0 (59.0, 75.0) |
| Range | 23.0, 97.0 | 36.0, 88.0 | 23.0, 97.0 | 26.0, 94.0 |
| **Hypertension** | 4,421 (59.7%) | 65 (57.0%) | 4,339 (59.6%) | 147 (61.5%) |
| **Diabetes Mellitus** | 1,796 (24.3%) | 49 (43.0%) | 1,743 (23.9%) | 102 (42.7%) |
| **Persistent albuminuria categories** |  |  |  |  |
| A1 | 4,749 (64.1%) | 23 (20.2%) | 4,725 (64.9%) | 47 (19.7%) |
| A2 | 1,984 (26.8%) | 34 (29.8%) | 1,941 (26.7%) | 77 (32.2%) |
| A3 | 672 (9.1%) | 57 (50.0%) | 614 (8.4%) | 115 (48.1%) |
| **GFR categories** |  |  |  |  |
| G3a | 4,695 (63.4%) | 26 (22.8%) | 4,664 (64.1%) | 57 (23.8%) |
| G3b | 2,171 (29.3%) | 36 (31.6%) | 2,126 (29.2%) | 81 (33.9%) |
| G4 | 539 (7.3%) | 52 (45.6%) | 490 (6.7%) | 101 (42.3%) |
| **CKD KDIGO classification** |  |  |  |  |
| Moderately increased risk | 3,266 (44.1%) | 12 (10.5%) | 3,256 (44.7%) | 22 (9.2%) |
| High risk | 2,448 (33.1%) | 12 (10.5%) | 2,429 (33.4%) | 31 (13.0%) |
| Very high risk | 1,691 (22.8%) | 90 (78.9%) | 1,595 (21.9%) | 186 (77.8%) |
| **Serum Creatinine (mg/dL)** |  |  |  |  |
| Mean (SD) | 1.4 (0.4) | 2.0 (0.7) | 1.3 (0.4) | 2.0 (0.7) |
| Median (IQR) | 1.3 (1.1, 1.5) | 1.9 (1.5, 2.5) | 1.3 (1.1, 1.5) | 1.9 (1.5, 2.4) |
| Range | 0.8, 3.8 | 1.0, 3.9 | 0.8, 3.8 | 0.9, 3.9 |
| **eGFR using CKD-EPI, ml/min/1.73m2** |  |  |  |  |
| Mean (SD) | 46.4 (9.6) | 33.7 (12.5) | 46.6 (9.4) | 34.5 (12.4) |
| Median (IQR) | 48.9 (40.8, 53.9) | 31.7 (23.2, 42.8) | 49.0 (41.1, 53.9) | 33.0 (23.5, 44.2) |
| Range | 15.0, 60.0 | 15.4, 59.8 | 15.1, 60.0 | 15.0, 59.8 |
| **Albumin-to-creatinine ratio, mg/g** |  |  |  |  |
| Mean (SD) | 235.5 (3,059.4) | 1,101.7 (1,614.1) | 229.3 (3,083.4) | 836.1 (1,283.1) |
| Median (IQR) | 14.2 (4.4, 62.7) | 302.0 (52.5, 1,663.9) | 14.0 (4.4, 59.4) | 270.9 (51.2, 992.4) |
| Range | 0.0, 144,870.6 | 2.5, 7,462.7 | 0.0, 144,870.6 | 0.2, 7,462.7 |
| **Urine Albumin (mg/ml)** |  |  |  |  |
| Mean (SD) | 7.6 (26.5) | 52.1 (73.5) | 7.1 (25.7) | 44.0 (62.3) |
| Median (IQR) | 0.9 (0.3, 3.7) | 16.0 (4.3, 71.6) | 0.9 (0.3, 3.5) | 15.3 (3.4, 56.5) |
| Range | 0.0, 658.0 | 0.2, 348.1 | 0.0, 658.0 | 0.0, 348.1 |
| **Urine Creatinine (mg/dl)** |  |  |  |  |
| Mean (SD) | 72.5 (47.7) | 64.8 (33.7) | 72.4 (47.0) | 69.8 (61.0) |
| Median (IQR) | 63.4 (41.4, 86.5) | 59.6 (39.6, 85.0) | 63.5 (41.3, 86.6) | 58.7 (41.0, 85.0) |
| Range | 0.1, 722.1 | 6.4, 218.6 | 0.1, 620.1 | 6.4, 722.1 |
| **Death at 2 years** | 563 (7.6%) | 77 (67.5%) | 563 (7.7%) | 77 (32.2%) |
| **Outcome at 2 years** |  |  |  |  |
| Alive w/o Kidney Failure | 6,842 (92.4%) | 0 (0.0%) | 6,717 (92.3%) | 125 (52.3%) |
| Death w/o Kidney Failure | 563 (7.6%) | 0 (0.0%) | 563 (7.7%) | 0 (0.0%) |
| Kidney Failure | 0 (0.0%) | 114 (100.0%) | 0 (0.0%) | 114 (47.7%) |
| **Death at 5 years** | 1,462 (19.7%) | 77 (67.5%) | 1,400 (19.2%) | 139 (58.2%) |
| **Outcome at 5 years** |  |  |  |  |
| Alive w/o Kidney Failure | 5,880 (79.4%) | 0 (0.0%) | 5,880 (80.8%) | 0 (0.0%) |
| Death w/o Kidney Failure | 1,400 (18.9%) | 0 (0.0%) | 1,400 (19.2%) | 0 (0.0%) |
| Kidney Failure | 125 (1.7%) | 114 (100.0%) | 0 (0.0%) | 239 (100.0%) |
| 1n (%) | | | | |